1. Home
  2. CHRS vs ATLO Comparison

CHRS vs ATLO Comparison

Compare CHRS & ATLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHRS
  • ATLO
  • Stock Information
  • Founded
  • CHRS 2010
  • ATLO 1903
  • Country
  • CHRS United States
  • ATLO United States
  • Employees
  • CHRS N/A
  • ATLO N/A
  • Industry
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • ATLO Major Banks
  • Sector
  • CHRS Health Care
  • ATLO Finance
  • Exchange
  • CHRS Nasdaq
  • ATLO Nasdaq
  • Market Cap
  • CHRS 186.0M
  • ATLO 187.5M
  • IPO Year
  • CHRS 2014
  • ATLO N/A
  • Fundamental
  • Price
  • CHRS $1.11
  • ATLO $21.20
  • Analyst Decision
  • CHRS Strong Buy
  • ATLO
  • Analyst Count
  • CHRS 4
  • ATLO 0
  • Target Price
  • CHRS $4.51
  • ATLO N/A
  • AVG Volume (30 Days)
  • CHRS 1.4M
  • ATLO 19.2K
  • Earning Date
  • CHRS 11-06-2025
  • ATLO 10-17-2025
  • Dividend Yield
  • CHRS N/A
  • ATLO 3.82%
  • EPS Growth
  • CHRS N/A
  • ATLO 82.57
  • EPS
  • CHRS 1.34
  • ATLO 1.80
  • Revenue
  • CHRS $277,728,000.00
  • ATLO $60,568,000.00
  • Revenue This Year
  • CHRS N/A
  • ATLO N/A
  • Revenue Next Year
  • CHRS $109.48
  • ATLO N/A
  • P/E Ratio
  • CHRS $0.82
  • ATLO $11.67
  • Revenue Growth
  • CHRS 152.07
  • ATLO 18.60
  • 52 Week Low
  • CHRS $0.71
  • ATLO $15.75
  • 52 Week High
  • CHRS $2.43
  • ATLO $21.48
  • Technical
  • Relative Strength Index (RSI)
  • CHRS 31.08
  • ATLO 52.71
  • Support Level
  • CHRS $1.09
  • ATLO $20.51
  • Resistance Level
  • CHRS $1.25
  • ATLO $21.47
  • Average True Range (ATR)
  • CHRS 0.13
  • ATLO 0.34
  • MACD
  • CHRS -0.04
  • ATLO -0.05
  • Stochastic Oscillator
  • CHRS 0.81
  • ATLO 50.52

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

About ATLO Ames National Corporation

Ames National Corporation is a United States-based bank holding company. It provides short-term and medium-term commercial, multi-family, and agricultural real estate loans, residential real estate loans, agricultural and business operating loans and lines of credit, equipment loans, vehicle loans, personal loans and lines of credit, home improvement loans and origination of mortgage loans for sale into the secondary market. The Banks also offer a variety of checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit and automated/video teller machine access. The banking segment generates revenues through personal, business, agricultural and commercial lending, and Others.

Share on Social Networks: